S, K.D., R, A.A., V, A.S., Anirban, B., K, B.B., Khadijah, B., S, C.D., J, C.D., Colette, D., A, H.P., Susan, H., Inmaculada, H., Nicolas, I., E, J.M.K., Marie, N.A., Ankur, P., D, S.K., S, V.M., & Liesl, Z. (2026). 2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement): A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2025.05.009
S KD, R AA, V AS, Anirban B, K BB, Khadijah B, et al. 2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement): A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. Journal of the American College of Cardiology. 2026; doi: 10.1016/j.jacc.2025.05.009
S KD, R AA, V AS, et al. 2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement): A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.[J]. Journal of the American College of Cardiology. 2026. DOI: 10.1016/j.jacc.2025.05.009.
@article{s2026,
author = {Kazi Dhruv S and Abdullah Abdul R and Arnold Suzanne V and Basu Anirban and Bellows Brandon K and Breathett Khadijah and Chew Derek S and Cohen David J and DeJong Colette and Heidenreich Paul A and Hennessy Susan and Hernandez Inmaculada and Isaza Nicolas and Joynt Maddox Karen E and Navar Ann Marie and Pandya Ankur and Sims Kendra D and Varghese Merilyn S and Zühlke Liesl},
title = {2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement): A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.},
journal = {Journal of the American College of Cardiology},
year = {2026},
doi = {10.1016/j.jacc.2025.05.009},
note = {PMID: 41003462},
}
TY - JOUR AU - Kazi Dhruv S AU - Abdullah Abdul R AU - Arnold Suzanne V AU - Basu Anirban AU - Bellows Brandon K AU - Breathett Khadijah AU - Chew Derek S AU - Cohen David J AU - DeJong Colette AU - Heidenreich Paul A AU - Hennessy Susan AU - Hernandez Inmaculada AU - Isaza Nicolas AU - Joynt Maddox Karen E AU - Navar Ann Marie AU - Pandya Ankur AU - Sims Kendra D AU - Varghese Merilyn S AU - Zühlke Liesl TI - 2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement): A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. T2 - Journal of the American College of Cardiology PY - 2026 DO - 10.1016/j.jacc.2025.05.009 AN - PMID:41003462 ER -
AIM: The "2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement)" describes a systematic approach for consistent implementation of "economic value statements" across ACC/AHA guidelines. It updates the cost-effectiveness threshold and proposes a new level of certainty framework that summarizes the strength of the available evidence. Additionally, it describes how cost-effectiveness analyses (CEAs) can help advance equity in population cardiovascular health. METHODS: A focused literature search was conducted from January 9, 2024, to February 2, 2024, encompassing English-language publications related to CEA methodology in PubMed, EMBASE, and the Cochrane Library, with publication dates ranging from 1973 to the present. Additional relevant studies published during the writing process (through June 25, 2024) were also considered by the writing committee. STRUCTURE: This Cost/Value Methodology Statement updates prior guidance regarding the incorporation of evidence from published CEAs into clinical guidelines. It provides guidance for identifying and synthesizing relevant high-quality evidence, developing economic value statements, and communicating level of certainty in such statements. It defines the US cost-effectiveness threshold as $120,000 per quality-adjusted life year gained, highlights special considerations related to cardiovascular drugs and devices, emphasizes health equity considerations when interpreting CEAs, and defines a reference case for future CEAs.